Table 2.
Baseline characteristics of patients who underwent next-generation sequencing using specimens obtained through endobronchial ultrasound-guided transbronchial needle aspiration.
Characteristics | All Cases | Success Cases | Failure Cases | p Value † |
---|---|---|---|---|
(n = 156) | (n = 130) | (n = 26) | ||
Age, years | 70 (31–91) | 70 (31–87) | 70 (51–91) | 0.54 |
Sex, male | 103 (66.0) | 84 (64.6) | 19 (73.1) | 0.50 |
Smoking history | 0.47 | |||
Current or past | 116 (74.4) | 95 (73.1) | 21 (80.8) | |
Never | 40 (25.6) | 35 (26.9) | 5 (19.2) | |
Tumor clinical stage | 0.81 | |||
II | 3 (1.9) | 3 (2.3) | 0 (0) | |
III | 64 (41.0) | 53 (40.8) | 11 (42.3) | |
IV | 77 (49.4) | 65 (50.0) | 12 (46.2) | |
Recurrence | 12 (7.7) | 9 (6.9) | 3 (11.5) | - |
Size of lymph nodes | 0.45 | |||
Short axis on CT, mm | 14.5 (5.2–66.8) | 14.6 (5.2–66.8) | 14.1 (7.5–43.7) | |
Necrotic finding on CT | 0.52 | |||
Positive | 70 (44.9) | 60 (46.2) | 10 (38.5) | |
Negative | 86 (55.1) | 70 (53.8) | 16 (61.5) | |
Location of lymph nodes | 0.62 | |||
Upper paratracheal (2R, 2L, 3p) | 11 (7.1) | 9 (6.9) | 2 (7.7) | |
Lower paratracheal (4R, 4L) | 60 (38.5) | 51 (39.2) | 9 (34.6) | |
Subcarinal (7) | 43 (27.6) | 34 (26.2) | 9 (34.6) | |
Hilar (10R, 10L) | 2 (1.3) | 1 (0.8) | 1 (3.8) | |
Interlobar and lobar (11, 12) | 19 (12.3) | 16 (12.3) | 3 (11.5) | |
Others (lung, pleura) | 21 (13.5) | 19 (14.6) | 2 (7.7) | |
Pathological diagnosis | 0.48 | |||
Adenocarcinoma | 101 (64.7) | 86 (66.2) | 15 (57.7) | |
Squamous cell carcinoma | 21 (13.5) | 18 (13.8) | 3 (11.5) | |
Other subtypes or not otherwise specified | 34 (21.8) | 26 (20.0) | 8 (30.8) | |
SUVmax on PET-CT | 0.15 | |||
≥2.5 | 127 (81.4) | 109 (83.8) | 18 (69.2) | |
<2.5 | 17 (10.9) | 13 (10.0) | 4 (15.4) | |
Not evaluated | 12 (7.7) | 8 (6.2) | 4 (15.4) |
Data are presented as number (%) or median (range). † Calculated using Fisher’s exact test or Mann–Whitney U test. CT, computed tomography; SUVmax, maximum standardized uptake value; PET, positron emission tomography.